2012 was a hectic year for Regulus Therapeutics Inc.It inked partnerships with AstraZeneca PLC and Biogen Inc., and raised $75 million from an October IPO and concurrent private placement to AZ.
The five-year old biotech ended the year with $95 million in cash, helping reduce its burn and providing enough to fund operations through 2015 Also see "AstraZeneca Taps Regulus...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?